Revisiting cell and gene therapies in Huntington’s disease
Open Access
- 21 April 2021
- journal article
- review article
- Published by Wiley in Journal of Neuroscience Research
- Vol. 99 (7) , 1744-1762
Abstract
Neurodegenerative movement disorders, such as Huntington's disease (HD), share a progressive and relentless course with increasing motor disability, linked with neuropsychiatric impairment. These diseases exhibit diverse pathophysiological processes and are a topic of intense experimental and clinical research due to the lack of therapeutic options. Restorative therapies are promising approaches with the potential to restore brain circuits. However, there were less compelling results in the few clinical trials. In this review, we discuss cell replacement therapies applied to animal models and HD patients. We thoroughly describe the initial trials using fetal neural tissue transplantation and recent approaches based on alternative cell sources tested in several animal models. Stem cells were shown to generate the desired neuron phenotype and/or provide growth factors to the degenerating host cells. Besides, genetic approaches such as RNA interference and the CRISPR/Cas9 system have been studied in animal models and human‐derived cells. New genetic manipulations have revealed the capability to control or counteract the effect of human gene mutations as described by the use of antisense oligonucleotides in a clinical trial. In HD, innovative strategies are at forefront of human testing and thus other brain genetic diseases may follow similar therapeutic strategies.Keywords
Funding Information
- European Regional Development Fund
- Fundação para a Ciência e a Tecnologia (POCI‐01‐0145‐FEDER‐029621, UIDB/04539/2020)
This publication has 105 references indexed in Scilit:
- The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2013
- Characterization of forebrain neurons derived from late-onset Huntington's disease human embryonic stem cell linesFrontiers in Cellular Neuroscience, 2013
- Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin ExpressionCell, 2012
- Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington’s disease patient cellsMolecular Brain, 2012
- Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD InvestigatorsBMC Neurology, 2009
- Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease MiceMolecular Therapy, 2009
- A patient with Huntington’s disease and long-surviving fetal neural transplants that developed mass lesionsActa Neuropathologica, 2008
- Allele‐specific silencing of mutant Huntington’s disease geneJournal of Neurochemistry, 2008
- Striatal progenitors derived from human ES cells mature into DARPP32 neuronsin vitroand in quinolinic acid-lesioned ratsProceedings of the National Academy of Sciences, 2008
- Disease-Specific Induced Pluripotent Stem CellsCell, 2008